Acne is often discussed as an individual clinical concern, especially during adolescence, but new global estimates show its burden is growing at population scale. A cross-sectional analysis using Global Burden of Disease Study 2023 data found that acne vulgaris increased substantially worldwide between 1990 and 2023 and is projected to continue rising through 2050.
The study, published online in JAMA Dermatology, was led by Pierina Parraga of Brigham and Women’s Hospital and colleagues. The researchers estimated that 54.4 million people were living with acne in 2023 under the study’s case definition. That equates to a global prevalence of 674.1 cases per 100,000 people.
The estimates frame acne as a major contributor to skin-disease disability even though it is not associated with mortality in the analysis. The authors calculated 1.17 million disability-adjusted life years, or DALYs, attributable to acne in 2023. DALYs combine years lived with disability and years of life lost to premature death; for acne, the burden in this assessment comes from disability rather than deaths.
Prevalence, incidence and disability all increased
The analysis estimated 27.8 million incident acne cases globally in 2023, a rate of 344.4 per 100,000 people. Of prevalent cases, 56% were among females and 44% among males.
More notably, the long-term trend moved in the same direction across the study’s main measures. From 1990 to 2023, global age-standardized incidence risk rose 67.3%, prevalence risk rose 63.6%, and the DALY rate rose 63.5%.
Age-standardized measures are used to compare populations over time while accounting for differences in age structure. The results therefore indicate that the upward pattern is not explained solely by a larger or older global population. Acne’s measured burden increased after adjusting for demographic composition.
The figures also underline why acne should not be dismissed as a trivial condition. The study found that its global DALY burden exceeded that estimated for basal cell carcinoma and was of a similar order of magnitude to the burdens reported for squamous cell carcinoma, melanoma and psoriasis. Such comparisons do not mean the conditions are clinically identical; they show that nonfatal skin disease can still create a substantial global disability burden.
What the 2050 forecast suggests
The researchers used demography-plus-autoregressive integrated moving average projections to estimate how the burden may change by 2050. Their forecast points to 37.5 million incident cases, 77 million prevalent cases and 1.65 million DALYs globally.
Those projections should be read as estimates, not certainties. The authors explicitly cautioned that long-range forecasts remain uncertain. Although the modeling incorporates projected demographic changes, it does not propagate uncertainty in the underlying Global Burden of Disease estimates and cannot account for future changes in health-care use or diagnoses.
That caveat is especially important for a condition affected by access to dermatology services, public awareness, diagnostic practices and treatment availability. A future rise in recorded cases could reflect changes in disease occurrence, changes in who obtains care, changes in diagnostic patterns, or some combination of those factors.
Even with that uncertainty, the direction of the study’s historical trend is clear: the estimated global burden increased over more than three decades. The forecast indicates that health systems should be prepared for continuing demand rather than assuming acne is a limited or declining concern.
Why disability measures matter
Acne does not cause death in the analysis, but that does not make its impact negligible. The DALY measure captures the years people spend living with health loss. For acne, that may encompass the symptoms and functional effects reflected in the Global Burden of Disease framework.
The study’s comparison with other skin disorders highlights a broader public-health point. Conditions that are common, long-lasting or frequently recurring can create large aggregate effects even if they are rarely life-threatening. Their burden can be distributed across millions of people rather than concentrated in a smaller population with severe disease.
That has implications for how resources are considered. The findings do not prescribe a specific treatment policy, but they provide a quantitative basis for including acne in planning for dermatology capacity, public-health research and access to care. Population-level measurement can help prevent common conditions from being overlooked because they are familiar.
Limits of a global estimate
The work relies on the Global Burden of Disease Study 2023 and its case definition, so the estimates are shaped by the data and modeling choices used in that framework. Global figures are useful for tracking broad patterns, but they cannot substitute for local information about access to diagnosis, treatment practices or differences between regions.
The authors also stress the limits of their future projections. Changes in health-care utilization and diagnosis could alter the observed burden in ways the model cannot anticipate. Forecasts extending to 2050 are therefore better treated as a planning signal than a precise prediction.
Still, the study provides a consistent global picture: acne prevalence, incidence and disability burden all rose from 1990 to 2023. If the modeled trend continues, the number of people affected and the associated disability burden will be considerably higher by mid-century. For a condition often framed as routine, the results make the case for taking its population impact seriously.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
